BGM Group enters the second week of May with a striking reversal in short positioning — borrowed shares have collapsed by nearly 70% over the past month, even as the cost of borrowing ticks up to a one-month high.
The story here is almost entirely about the unwind. Short interest fell to roughly 14,000 shares, a decline of about 70% from the peak of 141,000 shares touched in early April. At current float levels, that leaves SI at a negligible 0.03% of the free float — a level that carries no real bearish significance on its own. The drop has been swift and sustained: from over 100,000 shares on April 16, down through the 30,000s by late April, and barely above 14,000 now. Whatever pressure was building in early April has been thoroughly released.
The lending market now looks loose — almost entirely so. Availability of shares to borrow has risen to 9,999%, meaning there are vastly more shares available than are currently lent out. Earlier in the year the picture was very different: utilization peaked at 97% on April 3, with fewer than one share in the lending pool left unborrowed. That was the tightest the borrow market had been over the past 52 weeks. Today's reading represents a near-total reversal. Cost to borrow has risen about 19% over the week to 5.42% — still a modest rate for a micro-cap pharma stock — but that uptick looks more like normal variability than renewed short demand given how little is actually out on loan.
The broader picture on BGM reflects a micro-cap with highly concentrated ownership. The four largest shareholders — all individual insiders — collectively hold over 55% of outstanding shares, leaving a free float of just under 50 million shares. External institutional ownership is minimal: Invesco, State Street, and Geode Capital each hold token positions well below one-tenth of one percent. With no analyst coverage visible, no upcoming earnings date flagged, and no material options market to speak of, the usual positioning signals are absent. The stock closed at $0.293, down about 11.5% over the past month but up modestly on the day, with a market cap near $48 million.
The ORTEX short score has drifted lower through the past two weeks, from 30.9 on April 24 down to 28.3 today — reflecting the exit of short positions rather than any fresh pressure. Among correlated peers on Nasdaq, ADIL slipped 7.7% on the week while PLRX edged 1.7% higher, suggesting no uniform directional move across the space that would explain BGM's own softness.
What to watch: the next inflection is likely volume-driven. With availability effectively unlimited and short interest near zero, any meaningful price move will come from the demand side — the concentrated insider ownership means thin float dynamics remain in play whenever trading activity picks up.
See the live data behind this article on ORTEX.
Open BGM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
